CompletedNCT01098435
RDC-0313 or placebo for binge-eating disorder
About this title
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
Read the official source —Researchers compared RDC-0313 (ALKS 33) and placebo, tracking side effects to assess safety in adults with binge eating.
Medication studyAges 18+United StatesEating disorders
Understand this study
What did researchers investigate?
Researchers compared RDC-0313 (ALKS 33) and placebo, tracking side effects to assess safety in adults with binge eating.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Tucson and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 69
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT01098435
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder
Get this study by email
Recruitment & locations
CompletedTucson · Minneapolis · Manlius
3 more locations
- Raleigh
- Mason
- Toledo
Questions about this study
What did researchers investigate?
Researchers compared RDC-0313 (ALKS 33) and placebo, tracking side effects to assess safety in adults with binge eating.
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including RDC-0313 (ALKS 33) and Placebo.
Who was this study for?
Listed age limits: from 18 years.
